Progenics Pharmaceuticals — Proxy Contest (October 2019)
21 slides from Progenics Pharmaceuticals's proxy contest presentation, Oct 23, 2019
Slide 1: Creating Shareholder Value Through the Advancement of Cancer Treatment
Progenics Creating Shareholder Value Through the Advancement of Cancer Treatment Progenics. Find Fight and Follow"
Slide 2: Safe Harbor Statements - Important Information For Investors And Stockholders
Safe Harbor Statements - Important Information For Investors And Stockholders toapproprate registration or qunifenion nder the rcurties lve of uch juredevon No fering of recurter habe made except oy means of prospector meetin the requirement of section iO ofthe Us, Secures ‘et of 1999, se amended In
Slide 3: Safe Harbor Statements (Cont'd)
DE UlUlUr——C 1 e Safe Harbor Statements (Cont’d) < Cautionary Statement Regarding Forward-Looking Statements “hi presentation contig projections and other “Yorsardiookng ttements"eparing tre events, Ststements contained this communication tht refer to Progenic’etinste or aripte fre eso other ron hor
Slide 4: Executive Summary
Executive Summary ‘Asa follow-up toour Institutional Sharcholder Services ("SS") meeting on October 21, 2019 and in response to Velan’ IS presentation filed with the SECalzo on October 21, 12019, Progenice’ Board of Directore and Management Team supplement ther ISS presentation with the following: V
Slide 5: Executive Summary (Cont.)
Executive Summary (Cont.) Y _Velan possessed material non-public knowledge of the proposed transaction seven weeks before the deal was announced. Velan’s purchase of nearly 2% of Progenics’ shares with such material non-publicinformation raises significant concerns about its governance and ethical p
Slide 6: The Board Continues to Take Steps to Secure Progenics' Future
The Board Continues to Take Steps to Secure Progenics’ Future Based on Recent Shareholder Feedback PGNX Now PGNX and LNTH Together Strengthen Leadership and Governance H World-lass, Proven Leadership Team Korn Ferry processtoldentfy2 new Directors, ncludinganew i LUNTH's leadership team continuesto
Slide 7: Unlike a Straight Sale, PGNX Equity Holders Will Participate in All Synergies
Unlike a Straight Sale, PGNX Equity Holders Will Participate in All Synergies and Potential Future Upside in the Combined Company Having publicly and definitively rejected the transaction for several months and criticized Lantheus’ operating and stock performance, Velan shows zero commitment to inde
Slide 8: PGNX Conducted a Proper Process for a Radiopharmaceutical Company
Ne —— ° 1 e PGNX Conducted a Proper Process for a Radiopharmaceutical Company Y- Lantheus expressed Inbound interest in a combination. Progenics did not solicit interest from Lantheus before or after the arrival of Velan Good governance principles and fiduciary duties dictated Progenics evaluate the
Slide 9: Velan's Claimed Areas of Focus are Immediately Addressed Through the Lantheus Transaction
Velan’s Claimed Areas of Focus are Immediately Addressed with a Higher Degree of Certainty Through the Transaction with Lantheus + Ldentiication of new top-tier CEO Y—Anvexperienced and successful CEO who has a proven track record of ereating “273% in shareholder value) ceo / ee ” Established manage
Slide 10: Velan's Claimed Areas of Focus Addressed (Cont.)
Velan’s Claimed Areas of Focus are Immediately Addressed with a Higher Degree of Certainty Through the Transaction with Lantheus (Cont.) Financials & Financing Governance & Incentives If Velan con: Where Velan’s Nominees Would Focus" PYLNDA readiness "1095 clinical trialdesien AZEDRAbaskat wial desi
Slide 11: Shareholders Should Hold Velan Accountable for Questionable Securities Trading
Shareholders Should Hold Velan Accountable for Questionable « Securities Trading, Governance and Ethical Practices e aa iar publeknewlecgestourapoters NTH sao omerorme etn squad sae ee ns 3 uma snes Aust elon suns Oar i tg | ame | Consent Sktation rncponiey | | S60 i x square : aed m po 450 the desl
Slide 12: Velan Purposefully Omitted PGNX's Latest Settlement Offer
@, s° Velan Purposefully Omitted PGNX’s Latest Settlement Offer, Which Gave * Velan Everything they Previously Demanded, Including CEO Resignation e September 6, 2019 + topics (leesenstesoyvern ox sone sores elon tiseniestyene elon andoneseetesoy heneuiy recente Boordatumen See) “emcee © teach matbe
Slide 13: Velan's Proposed CEO, David Mims, is Not Qualified
a e = , id Mi i « Velan’s Board Member & Proposed CEO, David Mims, is NOT QUALIFIED as a Board Member, CEO or Acting CEO Candidate COEUR) - avid mis has never been the CEO of ANY Company ‘ANY Public Company + David Mimshas not worked on the management team ofa public company since 2008 No Role in th
Slide 14: Velan's Plan To Put $200 Million of Debt on Progenics Is Irresponsible
Velan’s Plan To Put $200 Million of Debt on Progenics Is IRRESPONSIBLE and Should Alarm Investors . = Progenics would considera variety of financing alternatives in the absence of a transaction with Lantheus = However, $200 million of debt— “non-recourse” or otherwise — is an IRRESPONSIBLE DEBT BURD
Slide 15: Shedding Light on Velan's False and Misleading Claims Surrounding Dr. Scheinberg
De Shedding Light on Velan’s False and Misleading Claims Surrounding Dr. Scheinberg’s “Conflicts” \Velan’s Misleading Statements PGNX Board Truthful Response “Dr. Scheinberg was compensated... for his service asa Progenics director. ‘Memorial Sloan Kettering (“MSK") has had recent issues regarding i
Slide 16: Velan's Potential Alarming Issues are Unfounded and Inaccurate
Velan’s “Potential Alarming Issues” are Unfounded and Inaccurate Velan’s Misguided Attacks Direct Screenshots rom Velan’s Investor Presentation” Not disclosing CPOC' import ban in August 2018 mere days before ain $75 milion na follow on offering if known a the time) snd nt dlosing IRs potential plan
Slide 17: Appendix
Appendix Progenics Find Fight and Follow"
Slide 18: Blue Earth Transaction Value is Not a Valid Comparison to Progenics' PyL
Blue Earth Transaction Value is Not a Valid Comparison to Progenics’ PyL Product ‘Axumin™ (fluciclovine F18) PyL (""F-DCFPyL) Indication PET imaging agent for prostate cancer PET imaging agent for prostate cancer. US Phase of Development ‘Approved (May 2016) Phase3 EU Phase of Development ‘Approved
Slide 19: Timeline of Velan Knowledge and Latest Settlement Offer
Timeline of Velan Knowledge and Latest Settlement Offer ‘ Lantheus smite private nonbinding indewtonofinerest to acquire Progen Proenisesues20 2019 earnings release ‘The velan Group issues pressreleasecritealot Progen. ‘he clsingpriceoftnePrognice shares declines 16.3% fom $8.65 on August to $3:900n
Slide 20: Timeline of Velan Knowledge and Latest Settlement Offer (cont'd)
Timeline of Velan Knowledge and Latest Settlement Offer (cont’d) September September September Septemberit September 16 September 18 ‘September 20 October 17 October 18 (TE buyssttal of 89.520 Progenice shares ot $862 ‘elon demands PORK appoint of arector(2Velanaominees snd 2 mutually gree upon nomi
Slide 21: Highly Leveraged Biotech and Pharmaceutical Companies have been Punished by Investors
Dee rr. fa eC s° Highly Leveraged Biotech and Pharmaceutical Companies have been « Punished by Investors e (sinmor) (575) ears) es ons) fes0%) ean) fas) tra) {ate Pamncrts Company ure Bue me oa (ess) “Srv Tmrestenne sue ans 3103 BI eas) Cows ons ne cus ‘0 oe 132 fees) a eerancs rom ima a8 22 fasra)
Progenics Pharmaceuticals — Proxy Contest (October 2019) on 6ix